Oncolytics Biotech receives new patent for pelareorep mechanism of use
Oncolytics Biotech Inc has secured new patent protection for pelareorep worldwide and obtained a method-of-use patent for its immunotherapy, with U.S. issuance expected soon and new protective applications planned.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed